1. Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis
- Author
-
Pedro Luiz Spinelli Coelho, Gustavo Lacerda da Silva Calestini, Fernando Salgueiro Alvo, Jefferson Michel de Moura Freitas, Paula Marcela Vilela Castro, and Tulio Konstantyner
- Subjects
Vacinas contra papillomavirus ,Efeitos adversos ,Adolescente ,Metanálise ,Segurança ,Pediatrics ,RJ1-570 - Abstract
Objective: To identify and quantify the adverse effects associated with the recombinant human papillomavirus (types 6, 11, 16 and 18) vaccine in adolescents. Data source: Systematic review of randomized clinical trials from PubMed, SciELO and Lilacs databases. Articles investigating the safety of the vaccine in subjects under 18 years and comparing the recombinant human papillomavirus types 6, 11, 16 and 18 vaccine with a control group were included. Meta-analyses were performed for the outcomes of pain, erythema, swelling and fever, using clinical trials with maximum Jadad score. Data synthesis: Fourteen studies were included. The most common adverse effects related to the human papillomavirus vaccine were effects with no severity (pain, erythema, edema, and fever). Five studies were used for the meta-analyses: pain-risk difference (RD)=11% (p
- Published
- 2015
- Full Text
- View/download PDF